Success Stories: NIW Approved for Biomedical Science Researcher Advancing Regenerative Seed Cells, Cancer Gene Targets, and Medical Education Innovation
Client’s Testimonial:
“Thank you very much for your excellent work.”
On February 25th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: New York
Approval Notice Date: February 25th, 2025
Processing Time: 1 year, 3 months, 16 days
Case Summary:
North America Immigration Law Group (NAILG) presented a proposed endeavor that integrates regenerative medicine, oncology, and medical-education innovation. The petition explains how developing seed cells for tissue and organ repair, identifying actionable gene targets for cancer, and modernizing basic medical training together advance U.S. diagnostics, therapy design, and workforce readiness.
Research Focus and Contributions ● Vision restoration research using gene therapy, small-molecule modulation of retinal pathways, and stem-cell-derived retinal progenitors for functional repair.
● Oncology studies are establishing a transcription-factor pathway as a biomarker and driver of metastasis, offering targets for therapy development.
● An integrated medical-curriculum framework that strengthens problem- and case-based learning with cross-disciplinary tools.
Research Impact and Metrics ● Peer-Reviewed Publications: 42 journal articles and 3 book chapters.
● Citations: 166 independent citations, including a paper ranked in a top citation percentile for its year.
● Peer-Review Service: At least 5 invited reviews for recognized journals.
Here is an anonymized excerpt from a recommendation letter that underscores the practical impact of her work:
“The [client] advances regenerative ophthalmology by clarifying molecular mechanisms of stem-cell differentiation and reducing barriers like tumorigenesis and immune rejection. In proliferative vitreoretinopathy models, [client] combined CRISPR/Cas9 nickase with a survivin-targeting small molecule to curb epithelial-to-mesenchymal transition, proliferation, and migration in retinal pigment epithelial cells. In glaucoma models, embryonic stem-cell–derived precursors migrated to the damaged retina and differentiated into retinal ganglion cells after transplantation. In retinitis pigmentosa models, purmorphamine activation of Müller glia yielded rod-like photoreceptors, highlighting a path to functional repair, work reflected by invitations to review for leading journals.”
Demonstrating Substantial Merit and National Importance We showed substantial merit by tying this work to urgent needs in eye disease and women’s cancer care, and national importance by linking it to the economic burden of vision loss and to physician-workforce shortages that improved training can address. Independent citations, percentile performance for a flagship article, expert letters, and a forward plan demonstrate significance beyond any single institution.
Well Positioned to Advance the Proposed Endeavor The client’s advanced training, ongoing U.S. research role, publication and citation record, and invitations to judge the work of others establish a clear capacity to continue delivering clinically relevant discoveries and education tools that benefit U.S. healthcare systems.
NIW Approval and Outlook Approved in 1 year, 3 months, and 16 days, this NIW recognizes a research agenda that strengthens U.S. diagnostics, cancer-therapy targeting, and medical-education efficiency. NAILG is proud to have guided this case and looks forward to the client’s continued contributions to regenerative medicine, oncology, and next-generation clinical training.